Caroline Palomeque
Stock Analyst at Ladenburg Thalmann & Co.
(0.10)
# 4,693
Out of 5,022 analysts
158
Total ratings
30.4%
Success rate
-11.5%
Average return
Main Sectors:
Stocks Rated by Caroline Palomeque
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ARDX Ardelyx | Reiterated: Buy | $16 | $3.38 | +373.37% | 2 | Aug 10, 2026 | |
| ATHE Alterity Therapeutics | Initiated Coverage: Buy | $10 | $3.49 | +186.53% | 1 | Jun 16, 2026 | |
| HRMY Harmony Biosciences Holdings | Initiated Coverage: Buy | $59 → $54 | $39.57 | n/a | 2 | Oct 25, 2023 | |
| KRYS Krystal Biotech | Initiated Coverage: Buy | $154 | $325.31 | n/a | 2 | Oct 25, 2023 | |
| HALO Halozyme Therapeutics | Reiterated: Buy | $58 | $106.94 | n/a | 7 | Sep 11, 2023 | |
| ASND Ascendis Pharma | Reiterated: Buy | $166 | $227.31 | n/a | 12 | Sep 7, 2023 | |
| CMPS COMPASS Pathways | Reiterated: Buy | $33 | $11.95 | n/a | 7 | Aug 16, 2023 | |
| AVXL Anavex Life Sciences | Reiterated: Buy | $40 | $1.89 | n/a | 24 | Aug 9, 2023 | |
| DNLI Denali Therapeutics | Reiterated: Buy | $54 | $20.53 | n/a | 14 | Aug 9, 2023 | |
| OCUL Ocular Therapeutix | Reiterated: Buy | $15 | $7.29 | n/a | 7 | Aug 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $61 | $7.42 | n/a | 12 | Aug 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $10 | $14.95 | n/a | 2 | Apr 29, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $5 | $3.44 | n/a | 5 | Apr 23, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $3 | $0.851 | n/a | 8 | Apr 4, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | n/a | $2.56 | n/a | 4 | Apr 1, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $6 | $0.2826 | n/a | 14 | Apr 1, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $9 | $1.00 | n/a | 13 | Mar 28, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | 1,332p → 1,357p | 509p | n/a | 2 | Mar 14, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $34 | $0.3559 | n/a | 3 | Mar 20, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $20 | $6.34 | n/a | 5 | Mar 13, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $9 | $2.03 | n/a | 6 | Mar 9, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $8 | $8.12 | n/a | 1 | Aug 8, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | n/a | $0.00001 | n/a | 1 | Jun 13, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | n/a | $0.001 | n/a | 1 | Jun 7, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | n/a | $2.56 | n/a | 1 | May 17, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | n/a | $0.10 | n/a | 1 | Apr 24, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $18 | $0.012 | n/a | 1 | Mar 2, 2016 |
Ardelyx
Aug 10, 2026
Reiterated: Buy
Price Target: $16
Current: $3.38
Upside: +373.37%
Alterity Therapeutics
Jun 16, 2026
Initiated Coverage: Buy
Price Target: $10
Current: $3.49
Upside: +186.53%
Harmony Biosciences Holdings
Oct 25, 2023
Initiated Coverage: Buy
Price Target: $59 → $54
Current: $39.57
Upside: n/a
Krystal Biotech
Oct 25, 2023
Initiated Coverage: Buy
Price Target: $154
Current: $325.31
Upside: n/a
Halozyme Therapeutics
Sep 11, 2023
Reiterated: Buy
Price Target: $58
Current: $106.94
Upside: n/a
Ascendis Pharma
Sep 7, 2023
Reiterated: Buy
Price Target: $166
Current: $227.31
Upside: n/a
COMPASS Pathways
Aug 16, 2023
Reiterated: Buy
Price Target: $33
Current: $11.95
Upside: n/a
Anavex Life Sciences
Aug 9, 2023
Reiterated: Buy
Price Target: $40
Current: $1.89
Upside: n/a
Denali Therapeutics
Aug 9, 2023
Reiterated: Buy
Price Target: $54
Current: $20.53
Upside: n/a
Ocular Therapeutix
Aug 8, 2023
Reiterated: Buy
Price Target: $15
Current: $7.29
Upside: n/a
Aug 3, 2023
Reiterated: Buy
Price Target: $61
Current: $7.42
Upside: n/a
Apr 29, 2019
Reiterated: Buy
Price Target: $10
Current: $14.95
Upside: n/a
Apr 23, 2019
Rated: Buy
Price Target: $5
Current: $3.44
Upside: n/a
Apr 4, 2019
Reiterated: Buy
Price Target: $3
Current: $0.851
Upside: n/a
Apr 1, 2019
Downgraded: Hold
Price Target: n/a
Current: $2.56
Upside: n/a
Apr 1, 2019
Reiterated: Buy
Price Target: $6
Current: $0.2826
Upside: n/a
Mar 28, 2019
Reiterated: Buy
Price Target: $9
Current: $1.00
Upside: n/a
Mar 14, 2019
Reiterated: Buy
Price Target: 1,332p → 1,357p
Current: 509p
Upside: n/a
Mar 20, 2018
Rated: Buy
Price Target: $34
Current: $0.3559
Upside: n/a
Mar 13, 2018
Rated: Buy
Price Target: $20
Current: $6.34
Upside: n/a
Mar 9, 2018
Rated: Buy
Price Target: $9
Current: $2.03
Upside: n/a
Aug 8, 2017
Rated: Buy
Price Target: $8
Current: $8.12
Upside: n/a
Jun 13, 2017
Rated: Buy
Price Target: n/a
Current: $0.00001
Upside: n/a
Jun 7, 2017
Rated: Buy
Price Target: n/a
Current: $0.001
Upside: n/a
May 17, 2017
Rated: Buy
Price Target: n/a
Current: $2.56
Upside: n/a
Apr 24, 2017
Rated: Buy
Price Target: n/a
Current: $0.10
Upside: n/a
Mar 2, 2016
Initiated Coverage: Buy
Price Target: $18
Current: $0.012
Upside: n/a